Canine and feline keratoconjunctivitis sicca cases requiring long-term tear replacement are typically formulated as sterile aqueous ophthalmic solutions with pH adjusted to 7.2–7.4 and osmolality maintained between 250 mOsm/kg and 350 mOsm/kg. When the veterinary-grade artificial tear API is specified as hypromellose USP substitution type 2208 or 2910, the formulation window is 0.25% w/v to 0.6% w/v; when specified as polyvinyl alcohol, the level is held at 1.4% w/v; when specified as sodium hyaluronate, the level is 0.1% w/v to 0.3% w/v. The hypromellose powder is first dispersed in a vortex-driven high-shear mixer with WFI preheated to 60 °C–70 °C, then transferred to a chilled jacketed vessel to complete hydration and eliminate gel clusters. The bulk solution is filtered through a 0.45 µm prefilter and a 0.22 µm polyethersulfone sterilising-grade membrane in series; upstream stainless-steel lines are sanitised by steam-in-place and the filling isolator is held at an overpressure of 15 Pa to 25 Pa. Multi-dose LDPE dropper bottles are produced on 12-head blow-fill-seal lines because the polymer solution is sterilised by filtration rather than terminal autoclaving to preserve the viscosity profile. The most frequently observed batch defect is viscosity loss after sterilising-grade filtration, which is controlled by keeping dissolved oxygen below 0.1 mg/L and eliminating residual hydrogen peroxide from upstream sanitisation cycles. Batch-to-batch viscosity variation is typically held within ±10% when hydration time is controlled. Compliance for this segment is driven by FDA 21 CFR 210 and 211 cGMP, USP<71>, USP<51>, USP<789>, USP<771>, and USP<785>; residual solvent testing aligns with VICH GL18 and elemental impurities with ICH Q3D. Terminal product types include 5 mL, 10 mL, and 15 mL multi-dose dropper bottles, and 0.3 mL to 0.5 mL single-dose twist-off containers.

What Limits Terminal Viscosity After Carbomer Neutralization in Equine Ophthalmic Gel Production?

For viscous gel tear replacements used in equine aqueous tear film instability, carbomer 940/980 grades are dispersed in cold WFI at 2 °C–8 °C at 0.20% w/w to 0.35% w/w and hydrated for 8 h to 12 h under vacuum agitation. The neutralisation step with tromethamine at pH 7.0–7.3 raises zero-shear viscosity to a target range of 4,000 mPa·s–15,000 mPa·s measured on a Brookfield RVDV-III Ultra with SC4-14 spindle at 1 rpm and 25 °C. Air entrainment during neutralisation is the primary processing conflict; residual microbubbles act as nucleation points for preservative adsorption and reduce optical clarity. Bubble removal is performed in a planetary mixer at -0.085 MPa to -0.095 MPa with a bottom-scraper speed of 12 rpm, while maintaining the vessel temperature below 25 °C to avoid viscosity drift. Because the final gel cannot be sterilised by membrane filtration at production viscosity, aseptic compounding is performed in a Grade B/Class 100 background with Grade A laminar-airflow filling; terminal sterilisation by heat is excluded because it collapses the carbomer structure. Compliance references include USP<911>, USP<785>, USP<51>, Ph. Eur. 2.2.9, and FDA 21 CFR 210/211. Terminal dosage forms include 3.5 g and 10 g ophthalmic gel tubes, and 10 mL multi-dose high-viscosity dropper bottles. The upper operational boundary is pH 7.6; overshooting neutralisation above this threshold produces irreversible clarity loss and a false low-viscosity reading due to polymer precipitation.

Premix powders and freeze-dried granules intended for sterile reconstitution in veterinary hospital pharmacies are manufactured with a target bulk density of 0.45 g/cm³ to 0.65 g/cm³ and a particle-size distribution where D90 does not exceed 150 µm; this prevents floating and lump formation during rehydration in WFI at 20 °C–25 °C. If the API is supplied as a lyophilised sodium hyaluronate cake, reconstitution to 0.1% w/v–0.3% w/v is completed within 15 min under gentle orbital agitation at 40 rpm. The lyophilisation cycle uses a freezing hold at -40 °C for 4 h, primary drying at -10 °C and 0.2 mbar for 12 h, then secondary drying at 25 °C for 6 h. The solution is then filtered through a 0.22 µm sterilising filter inside an ISO Class 5 laminar airflow workstation. Terminal product types produced by this route include 10 mL sterile multi-dose bottles for in-clinic use, 1 mL unit-dose syringes for avian and exotic animal ophthalmology, and 5 mL reconstituted irrigation aliquots. The compliance framework follows USP<797> for sterile compounding, USP<795> for preparatory non-sterile steps, USP<789> for particulate matter, and FDA 21 CFR 500 for veterinary drug status. Residual moisture is maintained below 2.0% for lyophilised cakes and below 0.5% for spray-dried granules; moisture above 3.0% is associated with polymer aggregation during accelerated stability storage at 40 °C/75% RH. Fill weight for granular premix sachets is specified from 0.25 g to 2.00 g, and the primary package is a double-laminated aluminium foil pouch with desiccant. The operational boundary for reconstituted product is use within 24 h when no preservative is present in the formulation.

Sodium Hyaluronate Injection-Grade Feedstock and Anterior Chamber Viscoelastic Parameters

For veterinary cataract surgery and anterior chamber maintenance, the injection-grade artificial tear API—when specified as sodium hyaluronate with molecular weight 1.5 MDa–2.5 MDa—is dissolved in phosphate-buffered saline at 1.0% w/v to 2.0% w/v using low-shear agitation at 4 °C to avoid chain scission. The zero-shear viscosity target is between 50,000 mPa·s and 500,000 mPa·s at 25 °C. Injection-grade systems are processed in ISO Class 5 isolators with sterile silicone-coated stainless-steel vessels; terminal heat sterilisation is not used because autoclave exposure at 121 °C for 15 min reduces high-molecular-weight hyaluronate viscosity by up to 30%. Terminal filling into 0.5 mL, 0.85 mL, and 1.0 mL presterilised glass syringes with Luer-lock cannula hubs is completed aseptically. Compliance for this segment is anchored to ISO 10993-1, ISO 13485, 21 CFR 820 in applicable jurisdictions, USP<71>, USP<789>, and USP<785>. Terminal product types include single-use prefilled ophthalmic viscosurgical device syringes, viscoelastic cannula kits, and intraoperative chamber-maintenance cartridges. The limiting incompatibility is the use of cationic preservatives or trace aluminium, which can cause crosslinking and precipitate formation in the anterior chamber; aluminium is controlled to below 10 µg/g in the API release specification via ICP-MS. Published data for specific veterinary ophthalmic viscosurgical device configurations is limited; therefore, molecular-weight distribution and zero-shear viscosity are revalidated for each lot rather than extrapolated from human-approved master files.

If a Mucoadhesive Ocular Insert Is Required for Feline Tear Film Retention

Compressed or solvent-cast ophthalmic inserts for feline patients with refractory tear film break-up can utilise the same veterinary-grade polymer API as a mucoadhesive matrix at 20% w/w to 60% w/w of the dry insert mass. In solvent-cast polyvinyl alcohol/hypromellose films, the API is dissolved in a 70/30 ethanol-water solution and cast at 55 °C onto a release liner; the resulting film thickness is controlled between 40 µm and 120 µm. For compressed inserts, a direct-compaction blend with mannitol and hydroxypropyl cellulose is compressed on a rotary tablet press at 6 kN to 12 kN; friability below 1.0% is required to prevent edge fractures during blister packaging. Terminal product types include 5 mm × 2 mm sterile single-use inserts in peelable foil blisters, and 8 mm sutureless rods for experimental equine corneal protection. Quality requirements are drawn from USP<701> disintegration, USP<905> uniformity of dosage units, USP<71> sterility, and ISO 10993-5 cytotoxicity. Published data for this specific veterinary configuration is limited; therefore insert formulation work is typically managed through design-of-experiments protocols rather than fixed compendial monographs. The measurable incompatibility is over-drying below 2% residual moisture, which embrittles the polymer matrix and increases insertion trauma.

In low-viscosity irrigation lines for veterinary corneal and conjunctival lavage, the API is blended at 0.05% w/v sodium hyaluronate or 0.25% w/v hypromellose into a balanced salt solution using an inline high-shear mixer with recirculation. The solution is filtered through a 0.22 µm sterilising-grade polyethersulfone filter. Hypromellose-containing irrigation products are terminally autoclaved at 121 °C for 15 min; sodium hyaluronate-containing irrigation products are aseptically filtered because autoclaving reduces viscosity through chain scission. Terminal products include 250 mL and 500 mL polycarbonate irrigation bottles and 15 mL unit-dose wash vials. Compliance references include USP<71>, USP<785>, USP<789>, ISO 10993-7, and FDA 21 CFR 210/211. The operational boundary is pH 6.8–7.4; filtration at temperatures below 15 °C produces excessive back-pressure and should be avoided for high-viscosity grades. Published data for specific veterinary irrigation formulations is limited to hospital-compounding protocols and device manufacturer compatibility data.